Medicine and Dentistry
Enzalutamide
100%
Androgen Receptor
33%
HDAC3
25%
Treatment Response
25%
Ataxia Telangiectasia
25%
Cell Death
25%
Malignant Neoplasm
16%
Cell Growth
16%
Growth Disorder
16%
Prostate Cancer
16%
Programmed Cell Death
8%
Androgen Receptor Antagonist
8%
Prostate Cancer Cell Line
8%
Androgen Deprivation Therapy
8%
Castration Resistant Prostate Cancer
8%
Neoplasm
8%
Autophagy
8%
Cancer Research
8%
Overall Survival
8%
Clinical Trial
8%
DNA Damage
8%
Cell Cycle
8%
Cell Line
8%
Cancer
8%
Checkpoint Signalling
8%
Pharmacology, Toxicology and Pharmaceutical Science
Enzalutamide
100%
Androgen Receptor
33%
Malignant Neoplasm
25%
Histone Deacetylase 3
25%
Prostate Cancer
25%
Ataxia Telangiectasia
25%
Growth Disorder
16%
Clinical Trial
8%
Androgen Receptor Antagonist
8%
Castration Resistant Prostate Cancer
8%
Overall Survival
8%
Neoplasm
8%
Androgen
8%
Biochemistry, Genetics and Molecular Biology
Enzalutamide
100%
Androgen Receptor
41%
Ataxia Telangiectasia Mutated
25%
Cell Death
25%
HDAC3
25%
Cell Growth
16%
Cancer Cell
8%
Clinical Trial
8%
DNA Damage
8%
Receptor Antagonist
8%
Overall Survival
8%
Cell Cycle
8%
Autophagy
8%
Programmed Cell Death
8%